Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Nutrients ; 12(6)2020 Jun 02.
Article in English | MEDLINE | ID: mdl-32498269

ABSTRACT

OBJECTIVE: The purpose of this study was to determine if Porphyra tenera extract (PTE) has immune-enhancing effects and is safe in healthy adults. METHODS: Subjects who met the inclusion criteria (3 × 103 ≤ peripheral blood leukocyte level ≥ 8 × 103 cells/µL) were recruited for this study. Enrolled subjects (n = 120) were randomly assigned to either the PTE group (n = 60) and were given 2.5 g/day of PTE (as PTE) in capsule form or the placebo group (n = 60) and were given crystal cellulose capsules with the identical appearance, weight, and flavor as the PTE capsules for 8 weeks. Outcomes were assessed based on measuring natural killer (NK) cell activity, cytokines level, and upper respiratory infection (URI), and safety parameters were assessed at baseline and 8 weeks. RESULTS: Compared with baseline, NK cell activity (%) increased for all effector cell-to-target cell ratios in the PTE group after 8 weeks; however, changes were not observed in the placebo group (p < 0.10). Subgroup analysis of 101 subjects without URI showed that NK cell activity in the PTE group tended to increase for all effector cell/target cell (E:T) ratios (E:T = 12.5:1 p = 0.068; E:T = 25:1 p = 0.036; E:T = 50:1 p = 0.081) compared with the placebo group. A significant difference between the two groups was observed for the E:T = 25:1 ratio, which increased from 20.3 ± 12.0% at baseline to 23.2 ± 12.4% after 8 weeks in the PTE group (p = 0.036). A significant difference was not observed in cytokine between the two groups. CONCLUSION: PTE supplementation appears to enhance immune function by improving NK cell activity without adverse effects in healthy adults.


Subject(s)
Adjuvants, Immunologic , Dietary Supplements , Immune System/immunology , Plant Extracts/administration & dosage , Plant Extracts/pharmacology , Porphyra/chemistry , Cytokines/metabolism , Double-Blind Method , Female , Healthy Volunteers , Humans , Killer Cells, Natural/immunology , Male , Middle Aged
2.
Am J Emerg Med ; 35(8): 1210.e1-1210.e4, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28438445

ABSTRACT

Pneumothorax can cause a variety of electrocardiographic changes. ST segment elevation, which is mainly observed in myocardial infarction, can also be induced by pneumothorax. The mechanism is presumed to be a decrease in cardiac output, due to increased intra-thoracic pressure. We encountered a patient with ST segment elevation with minimal pneumothorax. Coronary angiography with ergonovine provocation test and echocardiogram had normal findings. The ST segment elevation was normalized by decreasing the amount of pneumothorax. We reviewed the literature and present possible mechanisms for this condition.


Subject(s)
Electrocardiography , Pneumothorax/physiopathology , Radiography, Thoracic/methods , ST Elevation Myocardial Infarction/physiopathology , Adult , Chest Pain , Humans , Male , Pneumothorax/complications , Pneumothorax/diagnostic imaging , ST Elevation Myocardial Infarction/diagnostic imaging , ST Elevation Myocardial Infarction/etiology , Treatment Outcome
3.
Exp Mol Med ; 37(4): 269-75, 2005 Aug 31.
Article in English | MEDLINE | ID: mdl-16155403

ABSTRACT

The antiarrhythmic clofilium is an efficient blocker of hERG1 potassium channels that are strongly expressed in the heart. Therefore, derivatives of clofilium that emit positrons might be useful tools for monitoring hERG1 channels in vivo. Fluoro- clofilium (F-clofilium) was synthesized and its channel-blocking properties were determined for hERG1 and hEAG1 channels expressed in HEK?293 cells and in Xenopus oocytes. When applied extracellularly in the whole-cell patch-clamp configuration, F-cloflium exhibited a slower onset of block when compared with clofilium, presumably owing to its lower membrane permeability. When applied in the inside-out configuration at the intracellular membrane side, it blocked hEAG1 channels almost as efficiently as clofilium (IC50 1.37 nM and 0.83 nM, respectively). Similar results were obtained for hERG1, showing F-clofilium is a potent hERG1 and hEAG1 channel blocker once it has reached the intracellularly accessible target site at the channel. Using the (18)F-labeled analog we studied the in vivo binding and distribution of F-clofilium in mice and a dog. Greatest activity was found in kidneys and bones. A small but significant enrichment of activity in the dog myocardium known for its expression of cERG1 channels allowed to depict the myocardium of a living dog by PET. Thus, F-clofilium is a useful tool for imaging hERG channels in living organisms.


Subject(s)
Anti-Arrhythmia Agents/pharmacology , Ether-A-Go-Go Potassium Channels/antagonists & inhibitors , Positron-Emission Tomography , Potassium Channel Blockers/pharmacology , Animals , Anti-Arrhythmia Agents/pharmacokinetics , Cell Line , Dogs , ERG1 Potassium Channel , Electrons , Female , Inhibitory Concentration 50 , Kidney/metabolism , Mice , Mice, Inbred BALB C , Myocardium/metabolism , Potassium Channel Blockers/pharmacokinetics , Quaternary Ammonium Compounds/pharmacokinetics , Quaternary Ammonium Compounds/pharmacology , Tissue Distribution , Xenopus
SELECTION OF CITATIONS
SEARCH DETAIL
...